This week Pfizer seeks Emergency Use Authorization for their COVID-19 oral antiviral; A meta-analysis found commonly prescribed drugs were linked to orthostatic hypotension; A novel treatment is approved for polycythemia vera; A new program has been cleared to allow individuals to carry out remote endoscopy procedures; And the largest to date psilocybin trial shows promise in treatment-resistant depression.
The meta-analysis included 69 RCTs with a total of 27,079 patients.
Norepinephrine is a catecholamine indicated for restoration of blood pressure in adult patients with acute hypotensive states.
The phase 3 study was evaluating the efficacy and safety of ampreloxetine for the treatment of symptomatic neurogenic orthostatic hypotension in patients 30 years of age and older.
The FDA has approved Rezipres (ephedrine hydrochloride) for the treatment of clinically important hypotension occurring in the setting of anesthesia.
Within two to four months, increases, decreases in systolic BP seen in transmasculine, transfeminine adults, respectively
A non-integral crimped vial overseal may result in a non-sterile product.
Nexus Pharmaceuticals announced the launch of Emerphed™, a premixed, ready-to-use formulation of ephedrine.
The FDA approved the New Drug Application (NDA) for Emerphed (Nexus Pharmaceuticals), a premixed, ready-to-use formulation of ephedrine sulfate.
A recent report published in the New England Journal of Medicine describes the case of a patient with persistent skin discoloration associated with the use of the antiarrhythmic agent amiodarone. The 81-year-old man presented to the emergency department after a fall, which was eventually attributed to orthostatic hypotension. His medical history included atrial fibrillation and…
